The European Medicines Agency (EMA) announced that it is beginning a review of blood clots appearing in a handful of recipients of the Johnson & Johnson COVID-19 vaccine.
EMA recently concluded that blood clots associated with low blood platelet levels were a “very rare” side effect of Vaxzevria, the vaccine from AstraZeneca.
Four recipients of the Johnson & Johnson vaccine have had such blood clotting events. One of those individuals has died.
Get the full story from our sister site, Drug Discovery & Development.